Bli medlem
Bli medlem

Du är här


Recipharm AB: Exercise of the over-allotment option in relation to shares of series B in Recipharm


Further to the announcement by Recipharm AB (publ) ("Recipharm" or the
"Company") on 3 April, 2014, Recipharm today confirms that, in
connection with its initial public offering, Carnegie Investment Bank
AB (publ) and SkandinaviskaEnskildaBanken AB (publ) have exercised
the over-allotment option in full in respect of 2,517,884 existing
shares of series B in Recipharm.

Following the exercise of the over-allotment option, the main owners
Lars Backsell and Thomas Eldered[1]
will hold 16,578,123 shares[2]
in Recipharm, corresponding toapproximately 45 percent of the shares
and approximately 86 percent of the votes in the Company[3]

The banks have also notified Recipharm that the stabilisation period
in respect of the offer has ended today and confirmed that there have
not been any stabilisation transactions in respect of the offer.

For further information please visit or contact:
Thomas Eldered, CEO,, telephone: +46 8
602 52 10

Björn Westberg, CFO,, telephone: +46 8
602 46 20

This information is in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the
regulations of NASDAQ OMX Stockholm. This information was submitted
for publication on 11 April, 2014, at 07.30 CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry based in Sweden
employing some 1,500 employees. Recipharm offers manufacturing
services of pharmaceuticals in various dosage forms, production of
clinical trial material and pharmaceutical product development.
Recipharm currently manufactures more than 200 different products to
both Big Pharma and smaller research- and development companies.
Recipharm's turnover is approximately SEK 2.1 billion and the Company
operates development and manufacturing facilities in Sweden, France,
the UK, Germany and Spain and is headquartered near Stockholm.

For more information on Recipharm and our services, please visit

Important information
This announcement is not an offer to sell or a solicitation of any
offer to buy any securities issued by Recipharm in any jurisdiction
where such offer or sale would be unlawful.

In any EEA Member State, other than Sweden, that has implemented
Directive 2003/71/EC as amended (together with any applicable
implementing measures in any member State, the "Prospectus
Directive"), this communication is only addressed to and is only
directed at qualified investors in that Member State within the
meaning of the Prospectus Directive.

Any securities referred to herein have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the
"Securities Act"), and may not be offered or sold in the United
States absent registration or an exemption from registration under
the Securities Act. There is no intention to register any securities
referred to herein in the United States or to make a public offering
of the securities in the United States. Any securities sold in the
United States will be sold only to qualified institutional buyers (as
defined in Rule 144A under the Securities Act) pursuant to Rule 144A.

In the United Kingdom, this document and any other materials in
relation to the securities described herein is only being distributed
to, and is only directed at, and any investment or investment
activity to which this document relates is available only to, and
will be engaged in only with, "qualified investors" (as defined in
section 86(7) of the Financial Services and Markets Act 2000) and who
are (i) persons having professional experience in matters relating to
investments who fall within the definition of "investment
professionals" in Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high
net worth entities falling within Article 49(2)(a) to (d) of the
Order (all such persons together being referred to as "relevant
persons"). Persons who are not relevant persons should not take any
action on the basis of this document and should not act or rely on


the company B&E Participation AB.

Whereof 3,892,407 shares of series B and 12,685,716 shares of series

calculation also includes 1,367,097 shares of series B which has been
added through conversion of the Company's convertible bond programme
with the last day of conversion as of 5 April, 2014.

Recipharm AB (publ)
Corporate identity number 556498-4825
Streetaddress Lagervägen 7, JordbroTelephone+46 8 602 52 00
Postal address Lagervägen 7, SE-136 50 Jordbro Fax +46 8 81 87 03


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.